To include your compound in the COVID-19 Resource Center, submit it here.

Venturing into diabetes

Why Metacrine's investors are funding a chronic disease company

While many VCs have deemed chronic diseases such as diabetes a no-fly zone because of clinical development costs, investors in Metacrine Inc.'s $36 million series A round are taking a contrarian approach. The expectation is the company's underlying science and management team with a track record of exits will justify the funding.

Metacrine has

Read the full 548 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE